Breakthrough Chikungunya Vaccine of Valneva’s: Phase 3 trial Data
Valneva, a renowned global market leader in vaccine development, has published the research clinical data of its Chikungunya Vaccine candidate Phase 3, VLA1553. The groundbreaking results of VLA1553 can be found in the prestigious medical journal, The Lancet. With Chikungunya…
